Legend Biotech to Present at the 43rd Annual J.P. Morgan Healthcare Conference
CARVYKTI® Significantly Improved Minimal Residual Disease Negativity Compared to Standard of Care for Patients with Relapsed or Refractory Multiple Myeloma [Yahoo! Finance]
CARVYKTI® Significantly Improved Minimal Residual Disease Negativity Compared to Standard of Care for Patients with Relapsed or Refractory Multiple Myeloma
Legend Biotech Co. (NASDAQ: LEGN) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $83.00 price target on the stock.
Legend Biotech Co. (NASDAQ: LEGN) had its "outperform" rating re-affirmed by analysts at Royal Bank of Canada. They now have a $86.00 price target on the stock.